smithandnephewmasterform6
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of
1934
April
26, 2023
Commission
File Number 001-14978
SMITH & NEPHEW plc
(Registrant's
name)
Building 5, Croxley Park,
Hatters Lane, Watford, Hertfordshire, WD18 8YE,
England
(Address
of registrant's principal executive offices)
[Indicate
by check mark whether the registrant files or will file
annual
reports
under cover Form 20-F or Form 40-F.]
Form
20-F
X
Form 40-F
---
---
[Indicate
by check mark if the registrant is submitting the Form 6-K
in
paper
as permitted by Regulation S-T Rule 101(b)(1).]
Yes
No X
---
---
[Indicate
by check mark if the registrant is submitting the Form 6-K
in
paper
as permitted by Regulation S-T Rule 101(b)(7).]
Yes
No X
---
---
[Indicate
by check mark whether by furnishing the information
contained
in this
Form, the registrant is also thereby furnishing information to
the
Commission
pursuant to Rule 12g3-2 (b) under the Securities Exchange Act
of
1934.]
Yes
No X
---
---
If
"Yes" is marked, indicate below the file number assigned to
the
registrant
in connection with Rule 12g3-2 (b) : 82- n/a.
Smith+Nephew First Quarter 2023 Trading Update
26 April 2023
Smith+Nephew (LSE:SN, NYSE:SNN) trading update for the first
quarter ended 1 April 2023.
Highlights1,2
● Q1 revenue $1,356 million (2022: $1,306 million),
up 6.9% on an underlying basis and up 3.8% on a reported basis
(including -310bps foreign exchange impact)
● Continued strong growth from Sports Medicine &
ENT and Advanced Wound Management and improved performance from
Orthopaedics
o Sports
Medicine & ENT revenue up 10.0% underlying
o Advanced
Wound Management revenue up 7.9% underlying
o Orthopaedics
revenue up 3.9% underlying
● Established Markets revenue up 10.0% underlying as
procedure volumes strengthened, offsetting Emerging Markets, where
revenue was down -7.3% due to the expected impact in China from
volume-based procurement (VBP) and Covid
● Continued cadence of new product launches
contributing to growth
● Full year 2023 guidance unchanged, underpinned by
ongoing delivery of 12-Point Plan
Deepak Nath, Chief Executive Officer, said:
"I'm pleased with our revenue performance in the first quarter as
we delivered growth across all three franchises, including
improvement in Orthopaedics.
"We saw strong elective procedure volumes in our Established
Markets early in the quarter, which our surgical businesses are now
better placed to benefit from. We are consistently seeing
accelerated adoption of robotics and the new
CORI◊ Digital
Tensioner adds further differentiation to our platform and will
support better outcomes for patients.
"We are still in the early phases of the two-year life-cycle of our
12-Point Plan and are focused on driving
transformation."
Enquiries
|
|
Investors
|
|
Andrew Swift
|
+44 (0) 1923 477433
|
Smith+Nephew
|
|
|
|
Media
|
|
Charles Reynolds
|
+44 (0) 1923 477314
|
Smith+Nephew
|
|
|
|
Susan Gilchrist / Ayesha Bharmal
|
+44 (0) 20 7404 5959
|
Brunswick
|
|
Analyst conference call
An analyst conference call to discuss Smith+Nephew's first quarter
results will be held at 8.30am BST / 3.30am EDT on Wednesday 26
April 2023, details of which can be found on the Smith+Nephew
website at https://www.smith-nephew.com/en/about-us/investors/financial-resources#quarterly-reporting.
Notes
1.
All numbers given are for the quarter ended 1 April 2023 unless
stated otherwise.
2.
Unless otherwise specified as 'reported' all revenue growth
throughout this document is 'underlying' after adjusting for the
effects of currency translation and including the comparative
impact of acquisitions and excluding disposals. All percentages
compare to the equivalent 2022 period.
'Underlying
revenue growth' reconciles to reported revenue growth, the most
directly comparable financial measure calculated in accordance with
IFRS, by making two adjustments, the 'constant currency exchange
effect' and the 'acquisitions and disposals effect', described
below.
The
'constant currency exchange effect' is a measure of the
increase/decrease in revenue resulting from currency movements on
non-US Dollar sales and is measured as the difference between: 1)
the increase/decrease in the current year revenue translated into
US Dollars at the current year average exchange rate and the prior
revenue translated at the prior year rate; and 2) the
increase/decrease being measured by translating current and prior
year revenues into US Dollars using the prior year closing
rate.
The
'acquisitions and disposals effect' is the measure of the impact on
revenue from newly acquired material business combinations and
recent material business disposals. This is calculated by comparing
the current year, constant currency actual revenue (which includes
acquisitions and excludes disposals from the relevant date of
completion) with prior year, constant currency actual revenue,
adjusted to include the results of acquisitions and exclude
disposals for the commensurate period in the prior year. These
sales are separately tracked in the Group's internal reporting
systems and are readily identifiable.
Forward calendar
Results for the first half of 2023 will be released on 3 August
2023.
First quarter trading update
Our first quarter revenue was $1,356 million (2022: $1,306
million), up 6.9% on an underlying basis. Reported revenue growth
was 3.8% including a -310bps headwind from foreign
exchange.
The first quarter comprised 64 trading days, in line with the
equivalent period in 2022.
Consolidated revenue analysis for the first quarter
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1 April
|
|
2 April
|
|
Reported
|
|
Underlying
|
|
Acquisitions
|
|
Currency
|
|
|
|
2023
|
|
2022
|
|
growth
|
|
growth(i)
|
|
/disposals
|
|
impact
|
|
Consolidated revenue by franchise
|
|
$m
|
|
$m
|
|
%
|
|
%
|
|
%
|
|
%
|
|
Orthopaedics
|
|
548
|
|
541
|
|
1.3
|
|
3.9
|
|
-
|
|
-2.6
|
|
Knee
Implants
|
|
237
|
|
231
|
|
2.3
|
|
5.0
|
|
-
|
|
-2.7
|
|
Hip
Implants
|
|
152
|
|
149
|
|
1.8
|
|
4.6
|
|
-
|
|
-2.8
|
|
Other Reconstruction(ii)
|
|
23
|
|
20
|
|
16.3
|
|
19.7
|
|
-
|
|
-3.4
|
|
Trauma
& Extremities
|
|
136
|
|
141
|
|
-3.2
|
|
-0.8
|
|
-
|
|
-2.4
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Sports Medicine & ENT
|
|
422
|
|
396
|
|
6.5
|
|
10.0
|
|
-
|
|
-3.5
|
|
Sports
Medicine Joint Repair
|
|
228
|
|
220
|
|
3.8
|
|
7.3
|
|
-
|
|
-3.5
|
|
Arthroscopic
Enabling Technologies
|
|
149
|
|
141
|
|
5.6
|
|
9.1
|
|
-
|
|
-3.5
|
|
ENT
(Ear, Nose and Throat)
|
|
45
|
|
35
|
|
26.9
|
|
30.8
|
|
-
|
|
-3.9
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Advanced Wound Management
|
|
386
|
|
369
|
|
4.7
|
|
7.9
|
|
-
|
|
-3.2
|
|
Advanced
Wound Care
|
|
175
|
|
182
|
|
-3.4
|
|
1.0
|
|
-
|
|
-4.4
|
|
Advanced
Wound Bioactives
|
|
136
|
|
118
|
|
14.9
|
|
15.2
|
|
-
|
|
-0.3
|
|
Advanced
Wound Devices
|
|
75
|
|
69
|
|
8.4
|
|
12.9
|
|
-
|
|
-4.5
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
1,356
|
|
1,306
|
|
3.8
|
|
6.9
|
|
-
|
|
-3.1
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Consolidated revenue by geography
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
737
|
|
659
|
|
11.8
|
|
11.8
|
|
-
|
|
-
|
|
Other Established Markets(iii)
|
|
404
|
|
404
|
|
-
|
|
7.0
|
|
-
|
|
-7.0
|
|
Total Established Markets
|
|
1,141
|
|
1,063
|
|
7.3
|
|
10.0
|
|
-
|
|
-2.7
|
|
Emerging
Markets
|
|
215
|
|
243
|
|
-11.5
|
|
-7.3
|
|
-
|
|
-4.2
|
|
Total
|
|
1,356
|
|
1,306
|
|
3.8
|
|
6.9
|
|
-
|
|
-3.1
|
|
(i)
Underlying growth is defined in Note 2 on page 2
(ii)
Other Reconstruction includes robotics capital sales, our joint
navigation business and cement
(iii)
Other Established Markets are Australia, Canada, Europe, Japan and
New Zealand
Overview of the first quarter
All three franchises contributed to the encouraging first quarter
as we maintained our growth momentum from the end of 2022. Sports
Medicine & ENT and Advanced Wound Management again delivered
strong growth and Orthopaedics also delivered an improved
performance. We continued to be held back by supply challenges in
some raw materials and components, and expect this to remain a
headwind during 2023.
Group trading was driven by a good quarter in the Established
Markets. The US, our largest market, grew 11.8% (11.8% reported),
and Other Established Markets grew 7.0% (flat on a reported basis
reflecting a -700bps impact from foreign exchange). Overall, we saw
a stronger
environment for elective procedures in our Established
Markets as
healthcare systems saw higher volumes than anticipated,
particularly in the early part of the quarter. This benefitted our
surgical businesses which are now better placed
as a result of our work to improve product supply and commercial
execution.
In Emerging Markets, the -7.3% decline (-11.5% reported) was the
result of a slower quarter in China, as expected. Here growth
continued to be impacted by the implementation of the previously
disclosed hip and knee VBP programme, with an additional effect
from the renewed Covid waves that began in late 2022. These
resulted in reduced procedure volumes and slower shipments into the
channel for much of the quarter. The headwind from VBP will
continue until Q2 2023. Emerging Markets excluding China delivered
growth in the quarter, led by performance in India and Latin
America.
Orthopaedics
Our Orthopaedics franchise delivered revenue growth of 3.9%
(1.3% reported) in the quarter. Excluding China, Orthopaedics grew
by 9.0% underlying.
Knee Implants was
up 5.0% (2.3% reported) and Hip Implants was up 4.6%
(1.8% reported). We continued to benefit from our differentiated
portfolio of Knee Implants including double-digit growth from
JOURNEY II◊ and
strong momentum from the new cementless total knee LEGION
CONCELOC◊.
Hip Implants performance was led by double-digit growth from our
OR3O◊ Dual
Mobility Hip System. During the quarter we announced new data
supporting improved outcomes from our VISIONAIRE◊ Patient-Specific
Instrumentation for total knee arthroplasty compared with
conventional instrumentation.
Other Reconstruction revenue
was up 19.7% (16.3% reported), including strong growth from our
CORI Surgical System. We are benefiting from recent expansion of
CORI, including offering the only robotics-assisted revision knee
indication. We continue to invest behind the CORI platform and are
at the early stages of introducing our new CORI Digital Tensioner.
This is a proprietary device for soft tissue balancing in knee
replacement, and is the only tensioner for robotic assisted surgery
that enables surgeons to measure the ligament tension in a knee
prior to cutting bone. This allows surgeons to accurately measure
gaps in the patient's knee using quantifiable data and helps make
planning more objective and eliminates inconsistencies in surgery
from current manual or mechanical tools.
In Trauma &
Extremities revenue was
down -0.8% (-3.2% reported). A strong quarter of growth in the US
was offset by the continued impact of the previously disclosed
decision to exit this segment in China. We expect Trauma &
Extremities growth to accelerate as the year progresses as we lap
market exits made in 2022 and continue to drive
the EVOS◊ Plating
System.
Sports Medicine & ENT
Our Sports
Medicine & ENT franchise
delivered revenue growth of 10.0% (6.5%
reported).
Revenue in Sports Medicine Joint
Repair was up 7.3% (3.8%
reported). Performance was led by our shoulder
repair portfolio, including double-digit growth from our
REGENETEN◊ Bioinductive
Implant. During
the quarter we introduced the UltraTRAC◊ QUAD
ACL Reconstruction Technique, bringing together new tendon harvest
and preparation guides with our family of
ULTRABUTTON◊ Adjustable
Fixation Devices. These technologies work together to provide an
innovative procedural solution, expanding Smith+Nephew's ability to
address surgeon graft preference in knee
repair.
Arthroscopic Enabling Technologies revenue
was up 9.1% (5.6% reported),
with a good quarter in video, COBLATION◊ and
patient positioning.
ENT delivered
revenue growth of 30.8% (26.9% reported), reflecting the post Covid
recovery in tonsil
and adenoid procedure volumes. During
the quarter we announced new evidence demonstrating that COBLATION
Technology can accelerate patient recovery with fewer complications
compared with total tonsillectomy techniques.
Advanced Wound Management
We delivered revenue growth of 7.9% (4.7% reported) from
our Advanced Wound
Management franchise.
Advanced Wound Care revenue
was up 1.0% (-3.4% reported), including
a solid performance across most major regions against a strong
prior year comparator.
Advanced Wound Bioactives revenue
was up 15.2% (14.9% reported) driven by sustained
double-digit growth from our skin substitutes
portfolio.
Advanced Wound Devices revenue
was up 12.9% (8.4% reported) as we continued to deliver good growth
across both our PICO◊ and
RENASYS◊ Negative
Pressure Wound Therapy Systems.
12-Point Plan update
In July 2022 we announced our 12-Point
Plan to fundamentally change the way we operate and deliver
results. The 12-Point Plan is focused
on:
● Fixing
Orthopaedics, to regain
momentum across hip and knee implants, robotics and trauma, and win
share with our differentiated technology;
● Improving
productivity, to support
trading profit margin expansion; and
● Further accelerating
growth in
our already well-performing Advanced Wound Management and Sports
Medicine & ENT franchises.
On productivity, we have finalised the associated costs for our
manufacturing network and go-to-market optimisation workstream. In
aggregate, the benefits from these actions are expected to result
in more than $200
million of annual savings by 2025, as disclosed last quarter, for
around $275 million of restructuring costs over three
years.
Outlook
Full year guidance for 2023 is unchanged, with targets
of 5.0%
to 6.0% underlying revenue growth (around 5.0% to 6.0% reported
based on exchange rates on 20 April 2023) and a trading profit
margin of at least 17.5%.
About Smith+Nephew
Smith+Nephew is a portfolio medical technology business that exists
to restore people's bodies and their self-belief by using
technology to take the limits off living. We call this purpose
'Life Unlimited'. Our 19,000 employees deliver this mission every
day, making a difference to patients' lives through the
excellence of our product portfolio, and the invention and
application of new technologies across our three global
franchises of Orthopaedics, Advanced Wound Management and Sports
Medicine & ENT.
Founded in Hull, UK, in 1856, we now operate in more than 100
countries, and generated annual sales of $5.2 billion in 2022.
Smith+Nephew is a constituent of the FTSE100 (LSE:SN, NYSE:SNN).
The terms 'Group' and 'Smith+Nephew' are used to refer to Smith
& Nephew plc and its consolidated subsidiaries, unless the
context requires otherwise.
For more information about Smith+Nephew, please
visit www.smith-nephew.com and
follow us on LinkedIn, Instagram or Facebook.
Forward-looking Statements
This document may contain forward-looking statements that may or
may not prove accurate. For example, statements regarding expected
revenue growth and trading profit margins, market trends and our
product pipeline are forward-looking statements. Phrases such as
"aim", "plan", "intend", "anticipate", "well-placed", "believe",
"estimate", "expect", "target", "consider" and similar expressions
are generally intended to identify forward-looking statements.
Forward-looking statements involve known and unknown risks,
uncertainties and other important factors that could cause actual
results to differ materially from what is expressed or implied by
the statements. For Smith+Nephew, these factors include: risks
related to the impact of Covid, such as the depth and longevity of
its impact, government actions and other restrictive measures taken
in response, material delays and cancellations of elective
procedures, reduced procedure capacity at medical facilities,
restricted access for sales representatives to medical facilities,
or our ability to execute business continuity plans as a result of
Covid; economic and financial conditions in the markets we serve,
especially those affecting healthcare providers, payers and
customers (including, without limitation, as a result of Covid);
price levels for established and innovative medical devices;
developments in medical technology; regulatory approvals,
reimbursement decisions or other government actions; product
defects or recalls or other problems with quality management
systems or failure to comply with related regulations; litigation
relating to patent or other claims; legal and financial compliance
risks and related investigative, remedial or enforcement actions;
disruption to our supply chain or operations or those of our
suppliers (including, without limitation, as a result of Covid);
competition for qualified personnel; strategic actions, including
acquisitions and dispositions, our success in performing due
diligence, valuing and integrating acquired businesses; disruption
that may result from transactions or other changes we make in our
business plans or organisation to adapt to market developments;
relationships with healthcare professionals; reliance on
information technology and cybersecurity; disruptions due to
natural disasters, weather and climate change related events;
changes in customer and other stakeholder sustainability
expectations; changes in taxation regulations; effects of foreign
exchange volatility; and numerous other matters that affect us or
our markets, including those of a political, economic, business,
competitive or reputational nature. Please refer to the documents
that Smith+Nephew has filed with the U.S. Securities and Exchange
Commission under the U.S. Securities Exchange Act of 1934, as
amended, including Smith+Nephew's most recent annual report on Form
20-F, which is available on the SEC's website at www.
sec.gov, for a discussion of certain of these factors. Any
forward-looking statement is based on information available to
Smith+Nephew as of the date of the statement. All written or oral
forward-looking statements attributable to Smith+Nephew are
qualified by this caution. Smith+Nephew does not undertake any
obligation to update or revise any forward-looking statement to
reflect any change in circumstances or in Smith+Nephew's
expectations.
◊ Trademark
of Smith+Nephew. Certain marks registered in US Patent and
Trademark Office.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned thereunto duly authorized.
Smith
& Nephew Plc
(Registrant)
Date: April
26, 2023
By: /s/
Helen Barraclough
-----------------
Helen
Barraclough
Company
Secretary